Lilly and Merck Extend Immuno-oncology Collaboration
Eli Lilly and Merck have announced their existing collaboration will be extended with the aim to evaluate the safety and efficacy of the combination of Lilly’s Alimta (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).